Drugs / DIT101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07485504 | Apr 2026 → Oct 2028 expected | hematopoietic and lymphoid system neoplasm | Tcelltech Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DIT101 | “DIT101 is an investigational in vivo CAR-T cell therapy administered by intravenous infusion.” NCT07485504 ↗ |
| Modality | Cell therapy | “in vivo CAR-T cell therapy” NCT07485504 ↗ |
| Route | Intravenous | “administered by intravenous infusion” NCT07485504 ↗ |